Medrad has developed a second-generation injector of MR contrast media. The new product, called Spectris Solaris, will be available worldwide by March. It features enhancements that provide added control and versatility, according to the company. Solaris
Medrad has developed a second-generation injector of MR contrast media. The new product, called Spectris Solaris, will be available worldwide by March. It features enhancements that provide added control and versatility, according to the company. Solaris is compatible with MR scanners ranging from 0.2T to 2T. The company introduced its first-generation Solaris in 1996.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.